The TGF-β receptor II (TGFBR2) depleted CAR-T cells by CRISPR/cas9 promoted tumor elimination efficacy of CAR-T cells both in vivo and in vitro, which provides a novel method to improve CAR-T cells’ function in the TGF-β-rich tumor environment and promote CAR-T cells’ efficacy in solid tumors (73). The gene discussed is TGFB1; the disease is neoplasm.